Ribozymes are potential tools for genetic manipulation, and various naturally occurring catalytic RNAs have been dissected and used as the basis for the design of new endoribonuclease activities. While such cleaving ribozymes may work well in vitro, they have not proved to be routinely effective in depleting living cells of the chosen target RNA. Recently, trans-splicing ribozymes have been employed to repair mutant mRNAs in vivo. We have designed modi®ed trans-splicing ribozymes with improved biological activity. These allow accurate splicing of a new 3 H exon sequence into a chosen site within a target RNA, and in frame fusion of the exon can result in expression of a new gene product. These trans-splicing ribozymes contain catalytic sequences derived from a selfsplicing group I intron, which have been adapted to a chosen target mRNA by fusion of a region of extended complementarity to the target RNA and precise alteration of the guide sequences required for substrate recognition. Both modi®cations are required for improved biological activity of the ribozymes. Whereas cleaving ribozymes must ef®ciently deplete a chosen mRNA species to be effective in vivo, even inef®cient trans-splicing can allow the useful expression of a new gene activity, dependent on the presence of a chosen RNA. We have targeted trans-splicing ribozymes against mRNAs of chloramphenicol acetyltransferase, human immunode®ciency virus, and cucumber mosaic virus, and demonstrated trans-splicing and delivery of a marker gene in Escherichia coli cells. The improved trans-splicing ribozymes may be tailored for virtually any target RNA, and provide a new tool for triggering gene expression in speci®c cell types.
Introduction

Self-splicing group I introns
The Tetrahymena thermophila precursor rRNA contains a group I intron capable of catalysing its own excision (Cech, 1990; Michel & Westhof, 1990; Price & Cech, 1985) . Self-splicing of the intron requires presence of a guanosine cofactor and a divalent cation, either Mg 2 or Mn 2 , and occurs via two sequential transesteri®cation reactions (Figure 1(a) ). First, a free guanosine is bound to the ribozyme and its 3 H hydroxyl group is positioned to attack the phosphorous atom at the 5 H splice site. The guanosine becomes covalently attached to the 5 H terminus of the intron. Second, the phosphodiester bond located at the 3 H splice site undergoes attack from the newly freed 3 H hydroxyl group of the 5 H exon, giving rise to ligated exon sequences. These successive reactions are chemically similar and appear to occur at a single active site. The reactions of self-splicing are characterized by the formation of alternative RNA helices as the 5 H and 3 H splice sites are each brought to form similar base-paired conformations within the catalytic core of the intron. The intron-exon junctions are aligned along a complementary sequence termed thè`i nternal guide sequence'' or IGS Michel et al., 1989; Waring et al., 1986) . Clea- Figure 1 (legend opposite) vage at the 5 H splice site depends on formation of a base-paired helix P1 between the IGS and sequences adjacent the splice site. The presence of a UÁG``wobble'' base-pair positioned four, ®ve or six residues from the base of this helix de®nes the susceptible phosphodiester bond Murphy & Cech, 1989) . After cleavage, a portion of the P1 helix is displaced to allow formation of a new helix P10, due to complementarity between the IGS and sequences adjacent the 3 H splice site (Figure 1(a) ), and ligation of the exons appears to occur as a reverse of the ®rst cleavage reaction.
Catalytic activities
In order to better de®ne the structural and catalytic properties of the group I introns, exon sequences have been stripped from the``core'' of the Tetrahymena thermophila intron. Such RNAs retain enzyme activity and can interact with substrate sequences in trans. For example, when truncated forms of the intron are incubated with sequences corresponding with the 5 H splice junction, the fragments undergo guanosine-dependent cleavage in mimicry of the ®rst step in splicing . The substrate and endoribonucleolytic intron RNAs base-pair to form helix P1, and cleavage occurs after a U ÁG base-pair at the expected position. Phylogenetic comparisons and mutational analyses indicate that the nature of the sequences immediately adjacent the conserved uridine residue at the 5 H splice junction are not important for catalysis, provided the base-pairing of helix P1 is maintained Murphy & Cech, 1989) . The sequence requirements for 3 H splice site selection appear to lie mainly within the structure of the intron itself, in the form of helix P9.0, and the following guanosine residue which delineates the 3 H intron boundary. However, there is an additional requirement for 3 H exon sequences which are needed for the formation of helix P10 and ef®cient splicing. The importance of helix P10 has been demonstrated by analysis of intron mutants (Suh & Waring, 1990) . In addition, oligonucleotides have been ligated in trans, using a truncated form of the intron as a catalyst, an``external'' guide sequence and oligonucleotides which had been extended by a 5 H guanosine residue. Here, the substrate oligonucleotides corresponding with the 3 H exon sequences were aligned solely by the formation of P10-like helices on an external template prior to ligation .
Trans-splicing
Trans-splicing, the joining of exons contained on different RNAs, has been demonstrated in a number of living systems. For example, the 5 H untranslated portions of certain mRNAs in trypanosomes and Caenorhabditis elegans are ef®ciently transspliced from SL-RNAs (spliced leader RNA; Blumenthal, 1995) , which consist of the 5 H exon fused to sequences which can functionally substitute for U1 snRNA (small nuclear RNA) in mammalian snRNP-splicing extracts (Eul et al., 1995) . Arti®cial trans-splicing has been demonstrated for group I introns that have been split and coexpressed in Escherichia coli. In the ®rst case, a bacteriophage T4 thymidylate synthase gene (td) containing a group I intron was divided at the loop connecting the intron helix P6a. Transcripts of the td gene segments were shown to undergo trans-splicing in vitro, and to rescue dysfunctional E. coli host cells (Galloway-Salvo et al., 1990) . Known base-pairings (P3, P6 and P6a) and probable tertiary interactions between the segments allowed correct assembly and processing of the gene halves. Second, Sullenger & Cech (1994) have shown that the L21 deleted form of the T. thermophila rRNA group I intron is capable of splicing a H and 3 H exon sequences within the T. thermophila group I intron. Formation of helix P1 (green) is required for recognition of the 5 H splice site, which is positioned immediately 3 H to a conserved GÁ U wobble base-pair within the helix. Splicing is initiated by binding of a guanosine co-factor (G) to the intron and nucleophilic attack at the 5 H splice site. In the second step of splicing, the distal portion of helix P1 is displaced by sequences from the 3 H exon which form helix P10 (yellow). The 3 H hydroxyl group of the cleaved 5 H exon then attacks the precisely positioned 3 H splice site, resulting in ligation of the exons. Exon sequences are in upper case letters, intron sequences in lower case letters. The sequence of the ligated exons is shown below and an arrow indicates the ligation site. (:) shows wobble base-pairs in the paired region P1. (b) A schematic diagram of base-pairing between a model trans-splicing ribozyme and its target mRNA (red). A uridine residue (U) is chosen adjacent to the intended 5 H splice site. Compensating base changes within the ribozyme allow formation of helix P1, and an unpaired region, corresponding with loop 1 (L1) is maintained. Sequences with extended complementarity to the target mRNA are fused to the ribozyme, to allow an extensive base-paired interaction between the molecules. Helices P1, P10, and the antisense region are shaded in green, yellow and blue, respectively. Coding sequences are in upper case letters, intron sequences in lower case letters. After cleavage of the target mRNA, the 3 H exon is ligated to the 5 H portion of the target mRNA, to produce a novel fused messenger RNA. Expression of the 3 H exon depends on trans-splicing in frame with the coding sequence of the target mRNA. The sequence of the ligated exons is shown, and an arrow indicates the ligation site. (c) Schematic diagram of a model trans-splicing ribozyme base-paired to its target mRNA (red). Required sequences are labelled explicitly, while those which are not constrained are indicated as N. Conserved sequences within the ribozyme are also labelled explicitly, while those which can be altered to maintain conserved base-pairing or to provide a chosen 3 H exon are indicated as n or N. The P5abc region which is deleted in the negative control ribozymes is boxed.
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H exon into a target RNA containing a sequence corresponding with the normal 5 H splice site (CCCUCU/AA; Jones et al., 1996; Jones & Sullenger, 1997) . The 5 H exon and 5 H portion of the P1 helix has been deleted from the L21 form of the intron, and this RNA can interact with the target via a six nucleotide stretch of sequence complementarity. Trans-splicing resulted in the formation of translatable b-galactosidase messenger RNA in E. coli. These ribozymes have been shown to be active in mammalian cells (Jones et al., 1996; Jones & Sullenger, 1997) , and recently have been targeted against human myotonic dystrophy protein kinase and globin mRNAs, with alterations made to the ribozyme sequences that form helix P1 (Lan et al., 1998; Phylactou et al., 1998) . This method allowed the repair of mutant mRNAs in vivo, but the speci®city and ef®ciency of the reaction was low: in one case, at least ten different transcripts were recognized as target RNAs and tagged with the 3 H exon (Jones et al., 1996) . This may be due to the limited extent of the interaction between ribozyme and target RNAs which is comprised solely of a six basepair region of complementarity (helix P1). Also, the P10 interaction was not allowed for in these ribozymes. While the P10 interaction within the T. thermophila intron is not essential for the recognition of the 3 H splice site in vitro (Been & Cech, 1985) , it appears to increase the ef®ciency and ®delity of the second step of splicing, and is conserved in most group I introns analysed so far Lehnert et al., 1996; Michel & Westhof, 1990; Suh & Waring, 1990) .
In addition to mRNA repair, trans-splicing ribozymes could provide a route to speci®cally modifying cells expressing a chosen target mRNA, without the requirement for highly ef®cient catalysis in vivo. The effect of producing a small amount of spliced mRNA product can be substantially ampli®ed by the biological activity of its translation product. If trans-splicing ribozymes are to be used as reliable tools for new experiments or therapies, it is their biological effect and speci®city that is of importance. Therefore, we have established bioassays to enable rapid testing and improvement of the biological properties of these molecules. Here, we provide the ®rst description of a¯exible design for trans-splicing ribozymes that have improved biological activity over previous versions. These new ribozymes are: (i) tailored to particular target sites within chosen mRNAs, and, in contrast to previous work; are (ii) mutated to conserve both the P1 and P10 helices; and (iii) contain an additional region of 5 H terminal sequence that is complementary to the intended target RNA. Using a simple bioassay in bacteria, we have shown that it is possible to deliver b-galactosidase activity with a high degree of biological speci®city via trans-splicing. Single base changes within the target mRNA eliminate ribozyme-mediated gene delivery. We have constructed ribozymes targeted at four different sites in three different RNAs, and shown that they function in a highly precise manner in E. coli. These results demonstrate the feasibility of conditional delivery of new gene activities within living cells, depending upon the presence of a chosen target RNA.
Results
Design of improved trans-splicing ribozymes
Previous workers have used truncated forms of the group I intron of T. thermophila rRNA for transsplicing mediated mRNA repair (Sullenger & Cech, 1994; Jones et al., 1996; Jones & Sullenger, 1997; Lan et al., 1998; Phylactou et al., 1998) . The group I intron can also be converted into ribozymes capable of highly speci®c targeted gene delivery via trans-splicing. The ribozymes can base-pair to a chosen target mRNA, catalysing a precise endonucleolytic cleavage, and ligating a new 3 H exon to the target mRNA. For cells bearing the target mRNA, in frame fusion of the 3 H exon sequence will trigger expression of the new spliced gene. In order to construct these trans-splicing ribozymes, additional sequences must be fused to a catalytic domain of the Tetrahymena intron (nt 28 to 414) to allow recognition of a chosen target RNA, and to provide a new 3 H exon. Several parameters govern the design of the ribozymes.
Firstly, a target RNA and``5 H splice site'' must be chosen. In the ®nal trans-splicing complex, only the 5 H portion of the P1 duplex is contributed by the target RNA. A uridine residue is located here as part of a GÁ U wobble base-pair , found adjacent to the 5 H splice sites of all group I introns Lehnert et al., 1996; Michel & Westhof, 1990) . Therefore, a uridine within the target mRNA is chosen to de®ne the intended splice site. This is the sole sequence requirement in the target RNA (Figure 1(b) ).
Secondly, helix P1 must be altered to allow recognition of the chosen 5 H splice site. Having chosen a particular target site, compensating sequence changes must be made to the IGS in the 5 H portion of the ribozyme, in order to allow the formation of a suitable helix P1 between the target and ribozyme RNAs. The helix P1 should contain a G ÁU base-pair at the intended 5 H splice site located at the sixth position from the base of the helix. P1 extends for an additional three base-pairs past the intended 5
H splice site in the T. thermophila intron, and this is maintained in the trans-splicing model (Figure 1 (a) and (b)).
Thirdly, further adjustments must be made in the IGS to allow the formation of a stable P10 helix. The helices P1 and P10 overlap along the T. thermophila intron internal guide sequence (Suh & Waring, 1990) , and the second and third residues following both the 5 H and 3 H splice sites are complementary to the same residues in the IGS.
Fourthly, the exon sequences¯anking the 3 H splice site must be chosen to allow in frame fusion with the 5 H exon sequences derived from the target mRNA. We have also avoided in frame start codons positioned near the 3 H splice site, to minimise illegitimate translation of the exon.
Finally, a region of extended complementarity to the target mRNA is placed at the 5 H terminus of the trans-splicing ribozyme in order to increase its af®-nity and speci®city for the target RNA. An arbitrary length of around 45 residues was initially chosen. The T. thermophila group I intron contains a loop (L1) at the terminus of helix P1, and a short region of unpaired sequence is maintained between helix P1 and the added complementary region (Figure 1 (a) and (b)). Sequences similar to the target site, that might form a P1 helix in cis, should be avoided.
Ribozymes designed according to these guidelines may be useful for the conditional delivery of new gene activities in vivo, and in order to test this we have constructed ribozymes designed to transsplice the E. coli LacZ a-peptide coding sequence to sites within the Tn9 chloramphenicol acetyl transferase (CAT), cucumber mosaic virus (CMV) coat protein and human immunode®ciency virus (HIV) tat mRNAs. In each case, the target splice site was located at a uridine residue within the N-terminal coding sequence of the gene, and splicing should result in an in frame fusion of target mRNA and LacZ coding sequences. First, ribozyme activity was tested in vitro. Incubation of ribozyme and target RNA transcripts resulted in production of the expected trans-spliced RNA products (data not shown). The ribozymes were then co-expressed with target sequences in bacteria and the transformed cells were tested for the production of trans-spliced mRNAs and protein products in vivo.
Bioassay for ribozyme activity
We ®rst constructed a ribozyme targeted against the Tn9 CAT mRNA, and a uridine residue 18 nt downstream of the AUG translational start codon was arbitrarily chosen as the splice site. A sequence which included the a-peptide of E. coli b-galactosidase was selected as the 3 H exon (Figure 2(a) ). A trans-splicing ribozyme was designed following the rules described above, and constructed using oligonucleotide synthesis and PCR ampli®cation techniques. The altered ribozyme sequences required for splice site recognition are shown in Figure 2 (a). The ribozyme and target RNAs were introduced into E. coli cells using pET-derived (Novagen) plasmids and pACYC184 (Chang & Cohen, 1978) , respectively. The two plasmids bear different antibiotic resistance markers and compatible origins of replication. The ribozyme sequences were placed under control of the tac promoter (Amann et al., 1983; de Boer et al., 1983) and transcription was induced by the addition of IPTG to the medium. Cells expressing ribozyme and target RNAs were analysed for the presence of transspliced RNA product and b-galactosidase activity. As controls, we: (i) produced a truncated form of the ribozyme which did not contain extended complementarity to the target; (ii) constructed a ribozyme where the P10 interaction could not be formed; (iii) constructed defective ribozymes from which the P5abc region of the intron core had been deleted; and (iv) expressed the target and ribozyme RNAs separately in different cultures. The P5abc domain is required for correct folding of the T. thermophila intron, and its deletion results in loss of activity under physiological conditions (Joyce et al., 1989; Mohr et al., 1994) .
Accurate trans-splicing was expected to produce a novel fused RNA, and subsequent translation of the new product should result in a chimaeric protein containing the ®rst six amino acid residues of CAT fused to 89 amino acid residues derived from the N terminus of b-galactosidase. This fusion peptide was expected to complement the o-peptide of b-galactosidase (expressed in XL1-Blue E. coli cells carrying the F H plasmid (proAB lacI q lacZÁM15 Tn10(tet r ))), to produce b-galactosidase activity as a result of trans-splicing in vivo. The enzyme activity was measured in cell extracts, and by development of blue colonies on X-gal indicator plates (Miller, 1992) . Only cells that expressed the target RNA and an active anti-CAT ribozyme showed b-galactosidase activity after overnight growth on indicator plates (Figure 2 (b), colony a; Table 1) . As controls, we tested colonies that coexpressed the target RNA with the ÁP5abc inactive ribozyme (Joyce et al., 1989; Mohr et al., 1994) , and colonies that expressed either the ribozyme or the target RNA alone. b-Galactosidase activity could not be detected in any of the controls (Figure 2(b) , colonies b, c and d; Table 1 ). This indicated that the b-galactosidase activity detected after coexpression of the ribozyme with the target RNA was due to trans-splicing in vivo.
Importance of the antisense region
In order to gauge the importance of sequence complementarity between the ribozyme and target mRNA for ef®ciency of the trans-splicing reaction, anti-CAT ribozymes with various length antisense domains were tested for activity (Figure 3 ). The extent of complementarity between ribozyme and target varied from only nine nucleotides (helix P1) for a truncated ribozyme to a total of 55, 110, and 210 nt for ribozymes with additional antisense regions. Co-expression of the target RNA with the ribozyme without an extended antisense region gave rise to ten units of b-galactosidase activity, while the addition of 46 nt of complementary sequence resulted in a 39-fold increase of activity (412 units). Increasing the length of sequence complementarity to a total of 110 and 210 nucleotides resulted in 523 and 426 units of b-galactosidase activity, respectively ( Figure 3 ; Table 1 ). The antisense region of the ribozyme is clearly important for increased biological ef®ciency of the ribozyme. We also exchanged the antisense region for an unrelated sequence that is complementary to the HIV TAT gene (see below). This anti-CAT ribozyme with an HIV-speci®c antisense region pro-duced less b-galactosidase activity (one unit) than the ribozyme lacking an antisense region (ten units). This demonstrates that the CAT-antisense region increases the ef®ciency in a sequencespeci®c manner, and suggests that the presence of non-speci®c sequences may impair trans-splicing in vivo. No signi®cant levels of b-galactosidase activity were seen in the absence of target RNA, for all of the ribozymes (Table 1) .
Importance of helix P10
The design of these trans-splicing ribozymes also differs from those previously described (Jones et al., 1996; Lan et al., 1998; Phylactou et al., 1998; Sullenger & Cech, 1994) in the addition of a P10 helix. In the wild-type Tetrahymena intron, the IGS base-pairs with the 5 H and 3 H exons and aligns them for the second step of splicing. The formation of a P10 helix has been shown to increase 3 H splice site speci®city (Suh & Waring, 1990) . Mutation of sequences within the 3 H exon that are involved in formation of helix P10 (from 5 H -GGGGUA-3 H to 5 H -UUUCCC-3 H ; Figure 4 (a) and (d)), caused a 50-fold drop in the production of b-galactosidase activity in our bioassay (Table 1) . Because of the two nucleotide overlap of helices P1 and P10, the ®rst two nucleotides of helix P10 must be adapted to the target sequence. Therefore, we tested a ribozyme where the ®rst two base-pairs of P10 were not allowed for and helix P10 was comprised of four nucleotides only (Figure 4(b) ). This ribozyme, when tested in cells co-expressing the target, resulted in 420 units of b-galactosidase activity, similar to the construct with a six nucleotide-long helix P10 (Figure 4(a) ; Table 1 ). In addition, P10 was reduced to two and zero base-pairs, and this resulted in a severe drop of b-galactosidase activity, to 8.4 and 8.2 units, respectively. While the sequences involved in P10 formation are required for ef®cient in vivo activity, it should be feasible to use ribozymes with shorter P10 helices. This would allow the re-use of 3 H intron sequences for different trans-splicing ribozymes, as helix P10 would not need to be adapted for different target RNAs.
Importance of an extended helix P1
The previously described trans-splicing ribozymes (Jones et al., 1996; Lan et al., 1998; Phylactou et al., 1998; Sullenger & Cech, 1994 ) utilized a helix P1 that consisted of six nucleotides only. The helix P1 in the original cis-splicing Tetrahymena intron extends for another three base-pairs downstream of the 5 H splice site to a total of nine base-pairs (Figure 1(a) ). This was maintained in our design (see above). If extension of helix P1 was not necessary, designing new trans-splicing ribozymes would be easier as only six nucleotides rather then nine would have to be adapted to a new target. To test this, we constructed a ribozyme where helix P1 was allowed for six nucleotides only (Figure 4 (e)), with a P10 helix of four base-pairs. Co-expression of this ribozyme with the target resulted in a drop of b-galactosidase units from 412 to 101 units (25 %). This indicates that a``full-length helix'' P1 of nine nucleotides is important for higher biological ef®ciency of the reaction.
Trans-spliced RNA products
Cells expressing the various ribozyme and target RNAs were grown overnight with 2 mM IPTG to induce transcription of the ribozymes, harvested, and RNA was extracted. Spliced RNA products were ampli®ed using reverse transcription-polymerase chain reaction (RT-PCR) analysis. Putative spliced RNAs were reverse transcribed using a primer speci®c to the 3 H region of the ribozyme transcription unit. The resulting cDNA was PCR ampli®ed, using a 3 H nested primer and a targetspeci®c 5 H primer. Ampli®cation of the correctly spliced product would result in a 276 bp DNA product, containing the two ligated exon sequences. Figure 2(c) shows the result of a representative experiment. Products of expected size could only be detected in cells that expressed both the ribozyme (with 46 nt complementarity) and the target RNA (Figure 2(c), lane 1) . No bands corresponding with spliced product were ampli®ed from controls which contained the ÁP5abc inactive form of the ribozyme (lane 2), or where either the ribozyme or the target RNA were expressed alone (lanes 3 and 4, respectively). In order to exclude the possibility that the spliced product in lane 1 resulted from in vitro splicing during RNA extraction and/or reverse transcription, a culture expressing the ribozyme was mixed with a culture expressing the target RNA before analysis (Figure 2(c) , lane 5). Any product would be the result of in vitro splicing. No spliced product was detected, indicating that the band in lane 1 resulted from trans-splicing in vivo. Small amounts of correctly spliced products could also be ampli®ed from cells expressing the target RNA and ribozymes either with no antisense region, with the HIV-speci®c antisense region, or with a mutated helix P10 region. Quantitative RT- PCR con®rmed that the products were obtained at lower yield than for the intact ribozyme, and lower b-galactosidase activities were found (Table 1 , and data not shown). RT-PCR was also performed with the other described ribozymes when co-expressed with the target. In all cases, an ampli®ed band corresponding with the spliced product could be detected, as expected. In order to check the ®delity of trans-splicing, RT-PCR products were puri®ed, ampli®ed, and directly sequenced using a 3 H LacZ internal primer. The sequence of the RT-PCR ampli®ed fragments always corresponded with that of the predicted spliced product (Figure 2(a) and (d); data not shown).
The two anti-CAT ribozymes with 101 and 201 nt antisense regions were expressed without the target. No b-galactosidase activity could be detected, indicating that little productive cis-splicing occured, where the longer antisense region would fold back to form an illegitimate P1. To investigate the possibility of cis-splicing that would result in out-of-frame or non-translatable RNAs, RT-PCR analysis was performed with primers that would amplify any cis-spliced RNA product. The 5 H primer was homolgous to the 5 H end of the extended antisense region. No product could be ampli®ed (data not shown), indicating that the increased ef®ciency measured in the assays when the ribozymes were co-expressed with the target is due to more ef®cient transsplicing.
Targeting different RNAs
In order to test whether our model for the design of trans-splicing ribozymes is a general one, we constructed ribozymes that were directed against other target RNAs. The design with a nine basepair helix P1, a six base-pair helix P10, and antisense regions of 42 and 45 nt were used. Trans-splicing ribozymes could be useful for triggering gene expression in response to virus infection of a cell, and we have targeted trans-splicing ribozymes at sites within a plant and a human virus, cucumber mosaic virus and human immunode®ciency virus type I, respectively. We chose two splice sites within the CMV coat protein mRNA (Schwinghammer & Symons, 1977) , and one splice site in the mRNA encoding the transactivator protein (TAT) of HIV-I (Zhou et al., 1994) .
The two chosen splice sites on the CMV coat protein mRNA were located after uridine residues positioned 10 and 12 residues downstream of the start codon for translation. Two trans-splicing ribozymes were constructed, and termed anti-CMV(10) and anti-CMV(12), respectively. The nucleotide sequence of the 5 H region of the coat protein mRNA is highly conserved between sequenced CMV isolates, and we expect the ribozymes to exhibit a broad speci®city for different viral strains. A splice site was also chosen within the HIV transactivator (TAT) protein mRNA, located next to a uridine positioned 18 residues after the start codon. The target region chosen for the helix P1 interaction is entirely conserved between sequenced HIV-I isolates, and the sequences recognized by the antisense portion of the ribozyme are also highly conserved. We chose to keep b-galactosidase a-peptide coding sequences within the 3 H exon sequence, and the trans-splicing ribozymes were designed using the techniques described above. The anti-CMV(10) and anti-CMV(12) ribozymes were constructed with antisense domains of 42 nt, while that of the HIV ribozyme was 45 nt long. Schematic representations of the ribozymetarget complexes are shown (Figure 5(a) , (e) and (i)). In addition, defective ÁP5abc ribozymes were produced as negative controls.
Two arti®cial target mRNAs were also constructed by fusing a 60 nt CMV sequence or a 67 nt of HIV sequence to the N terminus of the green uorescent protein (GFP) gene. Thus, the ribo- H and 3 H splice sites. The wobble base-pair in P10 of the anti-HIV ribozyme was introduced to avoid an in frame stop codon after the trans-splicing reaction. Coding sequences are in upper case letters, intron sequences in lower case letters. The sequence of the ligated exons is given and an arrow indicates the ligation site. (b), (f) and (j) b-Galactosidase assays. The upper colony co-expressed the ribozyme with the target, the lower one expressed the inactive ÁP5abc control ribozyme with the target. Colonies containing the active ribozymes were incubated for different time periods to produce intense histochemical staining (overnight for anti-HIV, and two days for anti-CMV). (c), (g) and (t) RT-PCR assays. Results for RNA analysis of the following cultures are shown: lane 1, culture co-expressing the ribozyme (R) with the correct target RNA (T); lane 2, culture co-expressing the ÁP5abc ribozyme (R*) with the target RNA; lane 3, culture co-expressing the ribozyme with the mutated target RNA (T*); lane 4, culture expressing the ribozyme alone; lane 5, culture expressing the target RNA alone; lane 6, control, where a culture expressing the ribozyme was mixed with a culture expressing the target RNA prior to analysis. Arrows indicate ampli®ed spliced product, larger products derived from the target mRNA are also evident. (d), (h) and (l) The products derived from spliced products were directly sequenced. Sequences adjacent to splice sites are shown and arrows indicate the ligation site.
zymes could be challenged with long mRNA transcripts and cells expressing the chimaeric target RNA be easily visualized. We also produced mutated forms of the target mRNAs in order to provide a more stringent test of ribozyme speci®city. A uridine residue near each of the target splice sites was changed to guanosine, which prevented formation of an essential GÁU wobble basepair preceding the splice sites for the anti-CMV(10) and anti-HIV ribozymes, and which introduced a base-pair mismatch within helix P1 in the case of the anti-CMV(12) ribozyme.
Two approaches were taken for the initial testing of these ribozymes. In one set of experiments the anti-CMV ribozymes and the target mRNAs were maintained on separate compatible plasmids in E. coli, similar to the experiments described above for the anti-CAT ribozymes. In a second approach, the anti-CMV(10) and anti-HIV ribozymes were cloned with their corresponding target genes on single plasmids, with the genes orientated for divergent transcription. Similar results were seen for both approaches. All of the ribozyme and target genes had been placed under control of the tac promoter (Amann et al., 1983; de Boer et al., 1983) , and expression was induced in E. coli using IPTG. RT-PCR techniques were used to detect the expected spliced RNA products, and histochemical staining and enzyme assays were used to test for b-galactosidase activity in the transformed cells. RNA products and b-galactosidase activity were seen after coexpression of each of the three active ribozymes with their corresponding target RNAs ( Figure 5 ), whereas no detectable protein activity or RNA products were produced with the negative controls. For example, mutation of the CMV-target mRNA to alter a single nucleotide, positioned two residues upstream of the chosen splice site, eliminated trans-splicing with the anti-CMV(12) ribozyme ( Figure 5(g) ).
In order to quantitate the levels of enzyme activity produced after co-expression of the active ribozymes and target mRNAs, we assayed bacterial extracts. Expression of the anti-HIV ribozyme with its target gave rise to nine units of b-galactosidase activity, while the anti-CMV ribozymes produced little activity above background with this assay, which was less sensitive than histochemical staining (data not shown, but see Figure 5 (b) and (f)). In contrast, the anti-CAT ribozyme produced 412 units of b-galactosidase activity after expression with its target. The reason for the observed differences in activity is not clear; however, it is possible that ribozymes have different af®nities for their target RNAs, or that different sites in the target RNAs are more easily accessible to the ribozyme. Also, sequence alterations within helices P1 or P10 might affect catalytic ef®ciencies. Alternatively, N-terminal fusion of amino acid residues (encoded by the target mRNA) may modulate the a-peptide activity of the fused polypeptide product, and thereby alter b-galactosidase activity. Coexpression of the anti-CMV(10), anti-CMV(12), and anti-HIV ribozymes with their respective targets, resulted in detection of RT-PCR products of the size expected to result from correct splicing of the target and ribozyme RNAs (255, 257, and 267 basepairs, respectively; Figure 5(c) , (g) and (k)). Sequence analysis con®rmed that the products all contained the expected splice junction (Figure 5(d) , (h) and (l)). RT-PCR ampli®cation of cell extracts also resulted in longer products corresponding with the target RNAs (849 bp for the CMV target and 699 bp for the HIV target RNA), since these also contain binding sites for the primers (Figure 5(c), (g) and (k) ).
All of the trans-splicing ribozymes produced detectable trans-spliced RNA products and b-galactosidase activity when expressed in cells containing the intended target mRNA. Thus, the model for the design of trans-splicing ribozymes appears to be robust. It is of equal importance that no detectable RNA or b-galactosidase products were formed when the ribozymes (or target mRNAs) were expressed alone, or when the defective ÁP5abc forms of the ribozymes or mutated target mRNAs were used (Figures 2 and 5 ). There is no evidence for expression of the 3 H exon sequences due to illegitimate splicing to other mRNAs and subsequent translation. However, we cannot exclude the possibility that inactive products might be produced by trans-splicing to other RNAs.
Mutation of a single base at or near the chosen splice site in the target mRNA eliminates the production of trans-spliced RNA product (see Figure 5 (c), (g) and (k), lanes 3) and b-galactosidase activity (data not shown). In the case of the anti-CMV(10) and anti-HIV ribozymes and their mutated target mRNAs, an essential G ÁU wobble base-pair (Michel & Westhof, 1990) preceding each chosen splice site is disrupted, and the loss of catalytic activity is expected. In the case of the anti-CMV(12) ribozyme and its mutant target, a single base-pair, located two nucleotides upstream from the splice site in helix P1, is disrupted, and this also abolishes activity ( Figure 5 (g), lane 3; the U located two nucleotides upstream of the splice site was mutated to a G). This demonstrates a high degree of speci®city for the trans-splicing reaction and should allow the use of trans-splicing ribozymes to discriminate between closely related mRNA targets in other cells. Recently, we have established a trans-splicing ribozyme-based system for targeted gene delivery in yeast, using the diphtheria toxin A chain. It has been possible to selectively kill cells differing by a single nucleotide within a chosen target mRNA. Delivery of a toxin provides a considerably more sensitive indicator for illegitimate expression, and we have con®rmed that addition of an extended antisense domain to the ribozyme is a requirement for ef®cient and selective cytotoxicity in this system (B.G.A., U.K., H.M.G. & J.H., unpublished results). through compensating base changes. The P10 sequence element is conserved among group I introns related to that of Tetrahymena, and has been shown to be important for 3 H splice site selection during splicing (Suh & Waring, 1990) . In our initial model, we maintained the wild-type arrangement, with the potential for the formation of six basepairs. We subsequently shortened this to four, two and zero base-pairs, and tested the biological activity of the variants. Reduction of helix P10 to zero or two base-pairs caused an almost 50-fold drop in b-galactosidase activity, showing that P10 is clearly important for ribozyme activity in vivo. Two of the nucleotides required for formation of helix P10 also form part of helix P1, and we have shown that this portion of helix P10 is dispensible, provided that the remaining four base-pairs are maintained. The P1 sequence is determined by the choice of target site. Therefore, in future it should not be necessary to adjust the P10 sequences within the 3 H exon when targeting the ribozymes at different mRNAs. This will allow re-use of the 3 H exon sequences.
Biological specificity
The ribozymes appear to be biologically highly speci®c. Alteration of a single nucleotide near the chosen mRNA target site eliminates the production of b-galactosidase activity. We have mutated the conserved uridine adjacent to the intended splice site within the HIV and CMV(10) target mRNAs, and the residue positioned two nucleotides upstream of the CMV(12) splice site. The latter might be regarded as a structural rather than catalytic mutant. The use of mutant target RNAs resulted in the loss of detectable trans-spliced product and b-galactosidase activity. This is a strong indication of the biological speci®city of these ribozymes, and suggests that the technique should allow distinction between closely related transcripts. We have seen the same high degree of speci®city in yeast experiments, where single base changes in the target mRNA can produce immunity to ribozyme-mediated cell ablation (Ayre et al., unpublished results).
Ribozyme-mediated gene delivery
These ribozymes catalyse in vivo trans-splicing in an effective and reproducible fashion. It may be possible to target trans-splicing ribozymes against virtually any RNA in a cell and to introduce new gene activities depending upon existence of the speci®c target RNA. This modi®ed design may also be useful for the construction of improved trans-splicing ribozymes for the repair of mutant mRNAs (Lan et al., 1998; Phylactou et al., 1998) , but this requires ef®cient catalysis. It seems likely that inclusion of a helix P10 and extension of P1 will be of bene®t; however, addition of an antisense region may be problematic due to potential base-pairing with the 3 H exon sequences which would be identical to the target RNA sequences. This might be circumvented by alteration of the codon usage of the 3 H exon or by use of a related gene, to reduce the amount of intra-ribozyme basepairing between the antisense region and the 3 H exon.
The``hammerhead'' class of self-cleaving RNAs was used as a basis for the design of highly speci®c endoribonucleases, which could be targeted at a chosen mRNA (Haseloff & Gerlach, 1988) . It was hoped that these might ®nd application for inhibiting gene expression in vivo. However, cleaving ribozymes must effectively deplete the target mRNA pool within the cell, and ef®cient access to the substrate and subsequent catalysis is essential for their use in vivo. In contrast, even inef®cient delivery of a trans-splicing ribozyme might allow the useful expression of new gene activities, dependent on the presence of a chosen RNA. The effects of producing a small amount of spliced mRNA product can be substantially ampli®ed by the biological activity of its translation product. This has two bene®ts. First, trans-splicing ribozymes are easier to assay. Even inef®cient catalysis can give rise to a fused RNA product that itself is unique and easily detected, and which may give rise to an assayable translation product. This is a considerable improvement compared with the problems of assaying the activity of endoribonucleolytic ribozymes, where in vivo catalysis results in merely depletion of the pool of target RNAs and generation of unstable and inactive products. We have already established simple bioassays for ribozyme delivery in E. coli and yeast (B.G.A., U.K., H.M.G. & J.H., unpublished results), and this will allow more rapid testing of methods for improved ribozyme expression in vivo. Second, the trans-splicing ribozymes might be useful as``RNA sensors''. Trans-splicing ribozymes could be used for the delivery of new gene activities in living cells, conditional upon the presence of a chosen mRNA species. For example, we have constructed ribozymes capable of splicing the diphtheria toxin A chain coding sequence into the CMV coat protein mRNA, and shown that yeast cells expressing the target RNA can be speci®cally ablated (Ayre et al., unpublished results). Ribozyme-targeted delivery of new gene activities could be used to speci®cally mark or kill cells that are virus-infected or of a particular differentiated or malignant type.
Materials and Methods
Ribozyme construction
All plasmids were constructed using standard techniques (Sambrook et al., 1989) . The ribozymes were cloned into a modi®ed pET17b vector (Novagen). The XhoI site in the multiple cloning site was destroyed by end-®lling, followed by religation. A tac promoter (Amann et al., 1983; de Boer et al., 1983) sequence TCT AGA TCT GTT GAC AAT TAA TCA TCG GCT CGT ATA ATG TGT GGA ATT GTG AGC GGA TAA CAA TTT CAC ACA AGC TT was synthesised and inserted
